Akorn, Inc. (NASDAQ:AKRX) Files An 8-K Other Events
Item 8.01. Other Events.

On November 28, 2016, Akorn, Inc. (the “Company”) announced that on November 22, 2016, the Patent Trial and Appeal Board (PTAB) ruled in favor of the Company in its inter partes review proceeding and found all the claims of the 6,114,319 patent related to the Durezol® formulation to be obvious. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. See attached exhibit index.

About Akorn, Inc. (NASDAQ:AKRX)

Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays. The Consumer Health segment is engaged in manufacturing and marketing branded and private-label animal health and OTC products. The Company’s Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. Its OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products.

Akorn, Inc. (NASDAQ:AKRX) Recent Trading Information

Akorn, Inc. (NASDAQ:AKRX) closed its last trading session up +0.02 at 22.40 with 1,059,097 shares trading hands.